HLA-DMB antibody (AA 81-100)

Catalog No. ABIN2621913

Product Details anti-HLA-DMB Antibody

Target: HLA-DMB (Major Histocompatibility Complex, Class II, DM beta (HLA-DMB))

Binding Specificity: AA 81-100

Reactivity: Human

Host: Rabbit

Clonality: Polyclonal

Conjugate: This HLA-DMB antibody is un-conjugated

Application: Western Blotting (WB), Immunohistochemistry (IHC), Immunohistochemistry (Paraffin-embedded Sections) (IHC (p))

Cross-Reactivity (Details): No cross reactivity with other proteins.

Purification: Immunogen affinity purified

Immunogen: A synthetic peptide corresponding to a sequence in the middle region of human HLA DMB(81-100aa NQKDTLMQRLRNGLQNCATH).

Isotype: IgG

Application Details

Application Notes: Optimal working dilution should be determined by the investigator.

Comment:

Target Species of Antibody: Human

Restrictions: For Research Use only

Handling

Format: Liquid

Reconstitution: Distilled water

Concentration: Lot specific

Buffer: Contains 5 mg BSA, 0.9 mg NaCl, 0.2 mg Na2 HPO4, 0.05 mg Thimerosal, 0.05 mg sodium azide per 100 μg antibody.

Preservative: Sodium azide, Thimerosal (Merthiolate)

Precaution of Use: This product contains Sodium azide and Thimerosal (Merthiolate): POISONOUS AND HAZARDOUS SUBSTANCES which should be handled by trained staff only.

Storage: 4 °C,-20 °C

Storage Comment: At -20°C for 1 year. After reconstitution, at 4°C for 1 month. It can also be aliquotted and stored frozen at -20°C for a longer time.Avoid freeze-thaw cycles.

Target Details for HLA-DMB

Target: HLA-DMB (Major Histocompatibility Complex, Class II, DM beta (HLA-DMB))

Alternative Name: HLA-DMB (HLA-DMB Products)

Synonyms: RING7 antibody, D6S221E antibody, RT1.DMb antibody, RT1.Mb antibody, MHC-DMB antibody, major histocompatibility complex, class II, DM beta antibody, RT1 class II, locus DMb antibody, HLA-DMB antibody, RT1-DMb antibody, PATR-DMB antibody

Background: Name/Gene ID: HLA-DMB

Synonyms: HLA-DMB, D6S221E, DMB, MHC class II antigen DMB, MHC class II HLA-DMB, RING7

Gene ID: 3109

Pathways: Cancer Immune Checkpoints